Latest Herceptin news
Neratinib Not Superior to Trastuzumab in ERBB2-Breast CA
posted April 15th
by modernClinician Editorial Team
by modernClinician Editorial Team
Neratinib-paclitaxel is no better than trastuzumab-paclitaxel for progression-free survival in recurrent and/or metastatic ERBB2-positive breast cancer, although it may delay the onset and reduce the frequency of central nervous system progression, according to a study published online April 14 in JAMA Oncology.
Lapatinib + Trastuzumab May Rapidly Shrink Breast Tumors
posted March 10th
by modernClinician Editorial Team
by modernClinician Editorial Team
The drug combination of lapatinib (Tykerb) and trastuzumab (Herceptin) induces tumor regression or disappearance in 25 percent of human epidermal growth factor receptor 2 (HER2)-positive cancers in 11 days, according to research presented Thursday at the European Breast Cancer Conference, held from March 9 to 11 in Amsterdam.
Editor's Recommendations
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes 
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy 
Family History Drives Cancer Risk in BRCA Test Groups .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV Related Articles
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Setmelanotide Beneficial in Acquired Hypothalamic Obesity Monthly Specialist Briefings
Stay Connected
